Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7366 to 7380 of 7688 results

  1. COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 (ES24)

    This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.

    Evidence summary: COVID-19 rapid summary
    Published
    21 May 2020

  2. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    This guidance has been updated and replaced by NICE technology appraisal guidance 962.

    Technology appraisal guidance
    Published
    28 August 2019

  3. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    In development [GID-TA11199] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Kurin Lock for blood culture collection (MIB297)

    This medtech innovation briefing (MIB) has been replaced by NICE medical technologies guidance on Kurin Lock for blood culture collection.

    Medtech innovation briefing
    Published
    31 May 2022

  5. BPMpathway for rehabilitation support in joint replacement surgery (MIB319)

    MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.

    Medtech innovation briefing
    Published
    21 March 2023

  6. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development [GID-TA11189] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development [GID-TA11302] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  9. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development [GID-TA11001] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development [GID-TA11443] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. PICO negative pressure wound therapy for closed surgical incision wounds (MIB149)

    This advice has been updated and replaced by NICE medical technologies guidance 43.

    Medtech innovation briefing
    Published
    15 June 2018

  12. QAngio XA 3D/QFR imaging software for assessing coronary obstructions (MIB146)

    This advice has been updated and replaced by NICE diagnostics guidance 43.

    Medtech innovation briefing
    Published
    15 May 2018

  13. Reveal LINQ insertable cardiac monitor to detect atrial fibrillation after cryptogenic stroke (MIB141)

    This medtech innovation briefing (MIB) has been updated and replaced by NICE diagnostics guidance 41.

    Medtech innovation briefing
    Published
    16 February 2018

  14. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued [GID-TA11396]

    Technology appraisal guidance
    Discontinued

  15. Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065

    In development [GID-TA11588] Expected publication date: TBC

    Technology appraisal guidance
    In development